14 research outputs found

    Self-Regulation in Children with Neurodevelopmental Disorders “SR-MRehab: Un Colegio Emocionante”: A Protocol Study

    Get PDF
    Self-regulation refers to the ability to control and modulate behavior, and it can include both emotional and cognitive modulation. Children with neurodevelopmental disorders may show difficulties in self-regulation. The main objective of this study is to improve self-regulation skills in children between 6 and 11 years of age with neurodevelopmental disorders. Methodology: A randomized controlled trial will be conducted with the use of “SR-MRehab: Un colegio emocionante”, based on a non-immersive virtual reality system where virtual objects can be managed by children in a natural way using their hands. Children will be recruited from several schools of Granada (Spain) and they will be randomly allocated to two groups. An assessment will be conducted before and after the intervention and 24 weeks after the end of the intervention process. The experimental group will receive the intervention using virtual reality. The control group will receive a standard self-regulation program. Both interventions will be performed once a week for a total of 10 sessions. Changes in self-regulation, as well as the acceptability of technology with the use of SR-MRehab, will be evaluated. The results will be published and will provide evidence regarding the use of this type of intervention in children with neurodevelopmental disorders. Trial registration: Registered with code NCT04418921.Programa Estatal de Generacion de Conocimiento y Fortalecimiento Cientifico y Tecnologico del Sistema de I+D+i y del Programa Estatal de I+D+i Orientada a los Retos de la Sociedad, del Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion 2017 PID2019-108915RB-I00Teaching innovation project of the Degree in Occupational Therapy of the University of Granada about Emotional Skills 19-7

    When Virtual Assistants Meet Teledermatology: Validation of a Virtual Assistant to Improve the Quality of Life of Psoriatic Patients

    Get PDF
    Teledermatology has given dermatologists a tool to track patients’ responses to therapy using images. Virtual assistants, the programs that interact with users through text or voice messages, could be used in teledermatology to enhance the interaction of the tool with the patients and healthcare professionals and the overall impact of the medication and quality of life of patients. As such, this work aimed to investigate the effectiveness of using a virtual assistant for teledermatology and its impact on the quality of life. We conducted surveys with the participants and measured the usability of the system with the System Usability Scale (SUS). A total of 34 participants (30 patients diagnosed with moderate-severe psoriasis and 4 healthcare professionals) were included in the study. The measurement of the improvement of quality of life was done by analyzing Psoriasis Quality of Life (PSOLIFE) and Dermatology Life Quality Index (DLQI) questionnaires. The results showed that, on average, the quality of life improved (from 63.8 to 64.8 for PSOLIFE (with a p-value of 0.66 and an effect size of 0.06) and 4.4 to 2.8 for DLQI (with a p-value of 0.04 and an effect size of 0.31)). Patients also used the virtual assistant to do 52 medical consultations. Moreover, the usability is above average, with a SUS score of 70.1. As supported by MMAS-8 results, adherence also improved slightly. Our work demonstrates the improvement of the quality of life with the use of a virtual assistant in teledermatology, which could be attributed to the sense of security or peace of mind the patients get as they can contact their dermatologists directly within the virtual assistant-integrated system

    La empresa MAXCOLCHON apuesta por la Innovación Orientada por las Personas

    No full text
    Conocer los aspectos más importantes que genera una experiencia de uso satisfactoria en los potenciales usuarios de un producto y el proceso de toma de decisión de la compra es clave para garantizar el éxito. Para conocer los aspectos y saber cómo los perciben los perfiles poblacionales concretos a los que va orientado el producto es imprescindible escuchar la voz de los usuarios. La Innovación Orientada por las Personas facilita una metodología validada para incluir a las personas en todas las fases del proceso de desarrollo, convirtiendo al usuario objetivo del producto en un recurso activo de generación de valor para las empresas. En esta línea, la empresa MAXCOLCHON ha desarrollado junto con el Instituto de Biomecánica (IBV) un proyecto que tiene como objetivo identificar los aspectos clave que tienen en cuenta los usuarios a la hora de valorar el colchón ONE y tomar la decisión de compra. A partir de dicha información es posible, desde trabajar en el desarrollo o mejora de un producto, hasta identificar la mejor forma de orientar una campaña de marketing.Knowing the most important aspects that generate a satisfactory user experience among the potential users of a product, and the decisionmaking process involved in a purchase is key to guaranteeing success. In order to understand these aspects and how they are perceived by the specific demographic profiles to which the product is aimed, it is essential to listen to the voices of the consumers themselves. People-Oriented Innovation provides a validated methodology to include people in all phases of the development process, turning the target consumer of the product into an active resource that generates value for companies. In this regard, MAXCOLCHON has developed, alongside the Instituto de Biomecánica (IBV), a project to identify the key aspects that consumers take into account when evaluating a ONE mattress and when deciding whether or not to purchase it. This information can be used to work on the development or improvement of a product to identify the best way to channel a marketing campaign

    Self-Regulation in Children with Neurodevelopmental Disorders "SR-MRehab: Un Colegio Emocionante": A Protocol Study

    No full text
    Self-regulation refers to the ability to control and modulate behavior, and it can include both emotional and cognitive modulation. Children with neurodevelopmental disorders may show difficulties in self-regulation. The main objective of this study is to improve self-regulation skills in children between 6 and 11 years of age with neurodevelopmental disorders. Methodology: A randomized controlled trial will be conducted with the use of "SR-MRehab: Un colegio emocionante", based on a non-immersive virtual reality system where virtual objects can be managed by children in a natural way using their hands. Children will be recruited from several schools of Granada (Spain) and they will be randomly allocated to two groups. An assessment will be conducted before and after the intervention and 24 weeks after the end of the intervention process. The experimental group will receive the intervention using virtual reality. The control group will receive a standard self-regulation program. Both interventions will be performed once a week for a total of 10 sessions. Changes in self-regulation, as well as the acceptability of technology with the use of SR-MRehab, will be evaluated. The results will be published and will provide evidence regarding the use of this type of intervention in children with neurodevelopmental disorders. Trial registration: Registered with code NCT04418921.This study is part of a teaching innovation project of the Degree in Occupational Therapy of the University of Granada about Emotional Skills with code: 19-74 and it is part of a project submitted to the call for «Proyectos de I+D+i» of the Government of Spain, within the “Programa Estatal de Generación de Conocimiento y Fortalecimiento Científico y Tecnológico del Sistema de I+D+i y del Programa Estatal de I+D+i Orientada a los Retos de la Sociedad, del Plan Estatal de Investigación Científica y Técnica y de Innovación 2017–2020”, with the code PID2019-108915RB-I00.Ye

    Goles en césped artificial: más duradero y sostenible

    No full text
    Currently there are installed approximately 25 millions of square meters of artificial turf for contact sports use in Europe (football, rugby, etc.). It means that at the end of their cycle of life 400.000 tones of non-dangerous materials will be placed in controlled landfills. The first aim of this project is to increase the useful life of artificial turf pitches in good conditions of use; and the second objective is to reuse and/or recycle the materials of artificial turf surfaces at the end of their cycle of life with the aim of reducing at maximum the quantity of materials placed on landfills.Se estima que en Europa hay instalados en la actualidad aproximadamente 25 millones de metros cuadrados de césped artificial destinados a deportes de contacto (fútbol, rugby, etc.), lo que generará al final de su ciclo de vida útil alrededor de 400.000 toneladas de material considerado no peligroso que deberá ser trasladado a vertederos controlados. El objetivo de este proyecto es, en primer lugar, velar por un incremento de la vida útil de los campos de césped artificial en condiciones óptimas de uso para, una vez alcanzado el final de su ciclo de vida, reutilizar y/o revalorizar los materiales que componen este tipo de superficies deportivas, reduciendo al máximo la cantidad de material depositado en vertederos

    Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease

    Full text link
    BACKGROUND Patients with Crohn's disease (CD) responding to anti-tumor necrosis factor (anti-TNF) show great variability in serum drug levels, even within the therapeutic range. We aimed at exploring the role of inflammatory, genetic, and bacterial variables in relation to anti-TNF through levels in CD patients. METHODS Consecutive CD patients receiving stable doses of infliximab or adalimumab were included. Clinical and analytical parameters were recorded. Cytokine response, bacterial DNA translocation, and several immune-related genes' genotypes were evaluated, along with serum through anti-TNF drug levels. A linear regression analysis controlled by weight and drug regimen was performed. RESULTS One hundred nineteen patients were initially considered. Five patients on infliximab and 2 on adalimumab showed antidrug antibodies in serum and were excluded. One hundred twelve patients were finally included (62 on infliximab, 50 on adalimumab). Fourteen patients on infliximab and 15 on adalimumab (22.6% vs 30%, P = 0.37) were receiving an intensified drug regimen. C-reactive protein (CRP), fecal calprotectin, Crohn's Disease Activity Index, leukocyte count, and albumin levels in plasma were not significantly associated with infliximab or adalimumab levels in the multivariate analysis. Serum interleukin-10 (IL-10) levels were directly related to infliximab (Beta = 0.097, P < 0.0001) and adalimumab levels (Beta = 0.069, P = 0.0241). The best multivariate regression model explaining the variability of serum infliximab and adalimumab levels included IL-10. Predicted drug levels by this model robustly fitted with actual drug levels (R2 = 0.841 for infliximab, R2 = 0.733 for adalimumab). CONCLUSION Serum IL-10 is significantly related to serum anti-TNF levels in CD patients, showing how the disposition of anti-TNF drugs is significantly influenced by the degree of immunological activation

    La atención a la diversidad : diferentes miradas

    No full text
    Resumen basado en el de la publicaciónSe recogen las aportaciones de prestigiosos profesores y profesoras de diversas universidades españolas sobre la atención a la diversidad. Se reflexiona sobre la ética de la diversidad, la necesidad de asumirla como una responsabilidad compartida, la realidad y la respuesta a esta pluralidad en las aulas y desde la investigación, la propuesta de una respuesta actual en relación a las nuevas tecnologías, y todo ello sin olvidar otros espacios de inclusión como son la inserción laboral y el ocio como desarrollo integral.AndalucíaBiblioteca de Educación del Ministerio de Educación, Cultura y Deporte; Calle San Agustín, 5 - 3 planta; 28014 Madrid; Tel. +34917748000; [email protected]
    corecore